Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MLNR | O43193 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964120 | 0.88 | LMNA (0.56) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL6923805 | 0.85 | TBXA2R (0.49) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL11577394 | 0.85 | HSPB1 (0.68) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL8395820 | 0.84 | LMNA (0.59) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL7111696 | 0.82 | PTGS2 (0.51) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL6930116 | 0.82 | HSPB1 (0.49) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL6536062 | 0.82 | ALDH1A1 (0.49) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL8964117 | 0.81 | ALDH1A1 (0.71) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL2246787 | 0.81 | ERN1 (0.62) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL7822262 | 0.81 | LMNA (0.58) | MAPTKMT2ALMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513032-B | 4-Substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | AlzeCure Pharma AB (SE) | 2023-12-12 | — | — | US | disclosed |
| EP-3814335-B1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2021-12-02 | — | — | US | disclosed |
| EP-3814335-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | Alzecure Pharma AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513032-A | 4-substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-2970262-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105164127-A | Bromodomain inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | disclosed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| CN-1321153-A | telomerase inhibitors and methods of use thereof | GERON CORP (US) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | NTRK2, NTRK3, BDNF | MAPT 116/4885KMT2A 2828/4885LMNA 1455/4885 |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 1922/4885KMT2A 238/4885LMNA 1668/4885 |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | NTRK2, NTRK3, BDNF | MAPT 116/4885KMT2A 2828/4885LMNA 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.